Data protection Impressum

Vaccines

Lonza strengthens its bioconjugation capabilities in Visp with two major expansions, adding three new suites and creating 300 jobs to meet growing demand.

Lonza expands bioconjugation capacity in Visp and creates 300 jobs

12 November 2024

Alithea Genomics, which emerged from the EPFL in 2020, has distinguished itself within the life sciences sector with its cutting-edge RNA sequencing solutions.

Alithea Genomics embarks on next-phase growth with CHF 2.8 million funding

18 March 2024

Nicolas Collin, Co-Founder and CEO of the Vaccine Formulation Institute (VFI), discusses the innovative approach and global impact of their work in developing high-quality, accessible adjuvants for vaccines and why Geneva was chosen as the ideal location for VFI's impactful work.

Why the Vaccine Formulation Institute chose Western Switzerland

23 January 2024

The latest collaboration complements Vaxcyte’s strategy to commence the initial commercial launch of VAX-24, a vaccine that targets the prevention of invasive pneumococcal disease (IPD).

Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine

17 October 2023

CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process.

Siegfried and Lonza secure top positions in global pharmaceutical outsourcing rankings

16 October 2023

Since its Observer Country status since December 2015, Switzerland has participated in over 20 multinational clinical trials and infrastructure projects under the ECRIN banner, including platform trials on COVID-19.

European clinical research infrastructure bolstered as Switzerland becomes ECRIN member

5 July 2023

Top Stories Western Switzerland

Top Stories from Western Switzerland (April-June 2023)

3 July 2023

Chinese vaccine manufacturer CanSino Biologics sets up shop in Geneva to launch its inhaled Covid vaccine

10 October 2022

Improved COVID-19 vector vaccine candidate

4 August 2022

Berna Biotech Pharma and Swiss Biotech Center to develop second-generation covid-19 vaccine

5 May 2021

1 2